SCHEMBL5546006

SCHEMBL5546006

CC(O)(COC(=O)N1CCN(c2ccc(Cl)cc2)CC1)Cn1cc([N+](=O)[O-])nc1Cl

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.46
MAPT P10636 6/20 0.46
ALDH1A1 P00352 5/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
ENPP2 Q13822 4/20 0.43
HTT P42858 3/20 0.40
MAPK1 P28482 1/20 0.40
KMT2A Q03164 1/20 0.40
NPSR1 Q6W5P4 1/20 0.39
TP53 P04637 2/20 0.39
DRD2 P14416 1/20 0.38
DRD4 P21917 1/20 0.38
MGLL Q99685 1/20 0.38
KDM4E B2RXH2 1/20 0.38
GAA P10253 1/20 0.38
HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5546002 1.00 LMNA (0.46) LMNAMAPTALDH1A1SMN1; SMN2ENPP2
SCHEMBL5542473 0.93 MAPT (0.45) LMNAMAPTALDH1A1SMN1; SMN2ENPP2
SCHEMBL5542481 0.93 MAPT (0.45) LMNAMAPTALDH1A1SMN1; SMN2ENPP2
SCHEMBL5537206 0.92 MAPT (0.46) LMNAMAPTALDH1A1SMN1; SMN2ENPP2
SCHEMBL5537217 0.92 MAPT (0.46) LMNAMAPTALDH1A1SMN1; SMN2ENPP2
SCHEMBL5534954 0.91 ENPP2 (0.45) LMNAMAPTALDH1A1SMN1; SMN2ENPP2
SCHEMBL5534947 0.91 ENPP2 (0.45) LMNAMAPTALDH1A1SMN1; SMN2ENPP2
SCHEMBL5546111 0.91 MAPT (0.53) LMNAMAPTALDH1A1SMN1; SMN2ENPP2
SCHEMBL5546105 0.91 MAPT (0.53) LMNAMAPTALDH1A1SMN1; SMN2ENPP2
SCHEMBL5545923 0.91 ENPP2 (0.45) LMNAMAPTALDH1A1SMN1; SMN2ENPP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 LMNA 4152/4885MAPT 4117/4885ALDH1A1 355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.